Maravai LifeSciences (MRVI) Tops Q4 EPS by 2c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
Go back to Maravai LifeSciences (MRVI) Tops Q4 EPS by 2c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
March 1, 2021 6:10 AM EST
Credit Suisse analyst Erin Wilson Wright raised the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $34.00 (from $31.00) while maintaining a Outperform rating.... More